Peptide education
Liraglutide
Victoza · Saxenda
Liraglutide is a prescription peptide that activates the GLP-1 receptor. Victoza and Saxenda contain liraglutide, but their US labels describe different uses and dosing schedules. Both are injected under the skin once daily.
Liraglutide has large human trials and defined prescription uses. The indication, dose, side effects, and follow-up depend on the actual product.
Overview
Quick answer
Victoza is labeled for type 2 diabetes and a specific cardiovascular use. Saxenda is labeled for long-term weight reduction in specified populations.
What is liraglutide used for?
Victoza is labeled to improve glucose control in adults and children aged 10 and older with type 2 diabetes, alongside diet and exercise. It is also labeled to reduce major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. With diet and activity changes, Saxenda is labeled for long-term weight reduction in adults and children aged 12 or older with obesity and body weight over 60 kg, and in adults with overweight and a weight-related condition.
Is the dose the same for both products?
No. The adult Victoza label starts at 0.6 mg daily, then increases to 1.2 mg, with 1.8 mg as an option when additional glucose control is needed. Saxenda has a separate weekly escalation to an adult dose of 3 mg daily.
What did the weight-management trial find?
In a 56-week study of adults without type 2 diabetes, the group assigned liraglutide 3 mg daily lost an average of 8.4 kg, compared with 2.8 kg on placebo. Both groups received lifestyle counseling. The analysis carried forward the last available weight for missing measurements.
What are the major safety questions?
Nausea and other digestive effects are common. Both labels carry a boxed thyroid C-cell tumor warning based on rodent findings, with uncertain relevance to humans. Pancreatitis, gallbladder disease, dehydration-related kidney injury, and low blood glucose with certain diabetes drugs also need attention.
Evidence
Evidence snapshot
Glycemic control in the label's age groups, plus cardiovascular risk reduction in a specified adult population.
Long-term weight reduction with diet and physical activity in the label's specified populations.
The trial studied adults without type 2 diabetes and compared liraglutide 3 mg daily with placebo.
A major cardiovascular event composite was lower with liraglutide than placebo in adults with type 2 diabetes at high cardiovascular risk.
The labels cite rodent thyroid C-cell tumors; whether this occurs in humans is unknown.
Claims
Common claims vs evidence
| Claim | Human evidence | Mechanistic evidence | Verdict |
|---|---|---|---|
| Liraglutide can support weight reduction. | In a randomized study of 3,731 adults without type 2 diabetes, participants assigned liraglutide 3 mg daily lost more weight on average than those assigned placebo, with lifestyle counseling in both groups. | The Saxenda label describes reduced calorie intake and GLP-1 receptor activity in appetite regulation. | Supported in the studied population and in the Saxenda label's specified populations. |
| Liraglutide reduces cardiovascular events for everyone who takes it. | LEADER enrolled adults with type 2 diabetes at high cardiovascular risk. The primary composite occurred in 13.0% of the liraglutide group and 14.9% of the placebo group over a median of 3.8 years. | The trial supports a benefit in its studied high-risk diabetes population. Victoza's labeled cardiovascular indication is for adults with type 2 diabetes and established cardiovascular disease, not every user. | |
| The same liraglutide schedule applies to every product. | The SCALE weight trial and LEADER cardiovascular trial studied different populations and outcomes; neither established a single schedule for both products. | Incorrect. Victoza and Saxenda have different labeled uses and dose ranges. Saxenda also specifies a response check and a separate pediatric maintenance option. |
Bottom line
Main takeaway
Victoza and Saxenda share an ingredient, but their labeled purposes and doses are not identical.
SCALE enrolled adults without type 2 diabetes; LEADER studied adults with type 2 diabetes at high cardiovascular risk.
Separate the 3 mg weight trial in adults without diabetes from the cardiovascular trial in adults with type 2 diabetes at high risk.
Identity
What it is
Liraglutide is an altered version of human GLP-1. Its chemical structure, protein binding, and resistance to breakdown help it remain active longer than the naturally occurring hormone.
Victoza and Saxenda are prescription injections with different labels. The labels describe use with diet and exercise or physical activity, depending on the indication.
Use context
Routes, doses, and cycle patterns
Victoza and Saxenda are taken once daily, with different dose schedules for diabetes and weight management. The SCALE weight trial used liraglutide 3 mg daily alongside lifestyle counseling.
Human studies and product labels
Victoza adult label
- Purpose
- Type 2 diabetes and the label's cardiovascular indication
- Context
- US prescribing label
- Route
- Subcutaneous injection
- Amount
- 0.6 mg daily for one week, then 1.2 mg; 1.8 mg if needed after at least one week on 1.2 mg
- Frequency
- Once daily, without regard to meals
- Duration
- Ongoing treatment, with dose escalation as specified on the label
The 0.6 mg adult starting dose is for initiation, not glycemic control. For children aged 10 and older, the label starts at 0.6 mg and allows increases in 0.6 mg steps after at least one week at the current dose if further glucose control is needed, up to 1.8 mg daily.
Saxenda adult label
- Purpose
- Long-term weight reduction in eligible adults
- Context
- US prescribing label
- Route
- Subcutaneous injection
- Amount
- 0.6 mg daily, increasing weekly through 1.2 mg, 1.8 mg, and 2.4 mg to 3 mg daily
- Frequency
- Once daily, without regard to meals
- Duration
- Long-term treatment with a label-specified response assessment
The adult label calls for a weight check 16 weeks after initiation and discontinuation if loss is less than 4% of starting weight. It specifies different response and maintenance rules for pediatric patients.
SCALE weight trial
- Purpose
- Weight change in adults without type 2 diabetes
- Context
- Study-reported regimen
- Route
- Subcutaneous injection
- Amount
- Liraglutide 3 mg daily or placebo
- Frequency
- Once daily
- Duration
- 56 weeks
Both groups received lifestyle counseling.
Saxenda pediatric label
- Purpose
- Long-term weight reduction in eligible patients aged 12 and older
- Context
- US prescribing label
- Route
- Subcutaneous injection
- Amount
- Gradual escalation toward 3 mg daily; 2.4 mg daily may be used if 3 mg is not tolerated
- Frequency
- Once daily
- Duration
- The label assesses BMI after 12 weeks on the maintenance dose
The label specifies obesity and body weight over 60 kg for this age group. It has separate titration and response criteria for children, and its safety and effectiveness have not been established in pediatric patients with type 2 diabetes.
What varies
- Product and purpose: check the named label, indication, age criteria, and dose device.
- Other medicines: insulin and sulfonylureas can increase the risk of hypoglycemia when used with liraglutide.
- Missed treatment: the labels include restart instructions after more than three days without a dose; contact the prescriber rather than guessing.
- Combining products: the Saxenda label does not recommend using it with other liraglutide products or other GLP-1 receptor agonists.
Research
Research evidence
Randomized studies support effects on weight and cardiovascular outcomes, but their populations differ. The SCALE study did not enroll people with type 2 diabetes; LEADER enrolled people with diabetes and high cardiovascular risk. Neither study establishes the quality of an unapproved product sold under the same ingredient name.
| Study / evidence area | Population | Design | Product context | Main outcome | Limitations | Weight |
|---|---|---|---|---|---|---|
| SCALE Obesity and Prediabetes | 3,731 adults without type 2 diabetes, with obesity or overweight and qualifying conditions | Randomized, double-blind, placebo-controlled trial | Liraglutide 3 mg daily plus lifestyle counseling | At 56 weeks, mean weight loss was 8.4 kg with liraglutide and 2.8 kg with placebo. | The trial excluded people with type 2 diabetes. The primary analysis carried forward the last available measurement for missing values; 71.9% of the liraglutide group and 64.4% of the placebo group completed 56 weeks of treatment. Sensitivity analyses supported the primary results. | Strong |
| LEADER cardiovascular outcomes trial | 9,340 adults with type 2 diabetes and high cardiovascular risk | Randomized, double-blind, placebo-controlled trial | Liraglutide or placebo added to usual care | Cardiovascular death, nonfatal heart attack, or nonfatal stroke occurred in 13.0% versus 14.9%, respectively, over a median 3.8 years. | The enrolled high-risk diabetes population differs from a general weight-management population. | Strong |
Cautions
Safety and unknowns
- Both product labels carry a boxed warning about thyroid C-cell tumors seen in rodents. Human risk is unknown. The products are contraindicated with a personal or family history of medullary thyroid carcinoma or MEN2, and after serious hypersensitivity to liraglutide or product ingredients.
- Nausea, vomiting, diarrhea, and other digestive effects can occur. Severe or persistent symptoms may cause dehydration and kidney injury. The labels also warn about pancreatitis and gallbladder disease.
- Low blood glucose is a particular concern with insulin or sulfonylureas. Saxenda's label also reports hypoglycemia in its pediatric trial, whose participants did not have type 2 diabetes.
- Saxenda's label calls for discontinuation when pregnancy is recognized. Tell the treating team before anesthesia or deep sedation because delayed stomach emptying may affect procedural planning.
Product quality
Product identity and quality
Approved pens have product-specific instructions and labeled dose settings. FDA does not approve compounded drugs or review them for safety, effectiveness, and quality before marketing.
Product and concentration
An ingredient name alone does not identify the formulation, labeled use, or dose device.
Pharmacy and storage
Confirm the source and follow the instructions for the specific dispensed product.
Mechanism
How it is proposed to work
Liraglutide acts at GLP-1 receptors. When glucose is elevated, it helps stimulate insulin release and reduces glucagon secretion. It also delays stomach emptying and affects appetite and calorie intake.
The label reports 97% amino-acid sequence homology to human GLP-1 and an approximately 13-hour half-life after subcutaneous injection.
Self-association, protein binding, and resistance to enzymatic degradation contribute to the pharmacokinetic profile.
Details
Technical details
Sources
References
- 1.
FDA. Compounding and the FDA: Questions and Answers
FDA explains that compounded drugs are not FDA-approved and that FDA does not verify their safety, effectiveness, or quality before marketing.
- 2.
PubMed. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
doi:10.1056/NEJMoa1411892 PMID:26132939 NCT01272219
Placebo-controlled 56-week weight-management trial in adults without type 2 diabetes.
- 3.
PubMed. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
doi:10.1056/NEJMoa1603827 PMID:27295427 NCT01179048
Randomized cardiovascular outcomes trial in adults with type 2 diabetes and high cardiovascular risk.
- 4.
DailyMed. Victoza (liraglutide) injection prescribing information
Victoza indications, adult and pediatric dosing, pharmacology, and warnings.
- 5.
DailyMed. Saxenda (liraglutide) injection prescribing information
Saxenda indications, weight-management dosing, response assessment, and warnings.